Federal Register / Vol. 87, No. 74 / Monday, April 18, 2022 / Notices 22933 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Sensory-Motor 

Neuroscience Study Section. 

Date: May 25–26, 2022. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: John Bishop, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5182, 

MSC 7844, Bethesda, MD 20892, (301) 408– 

9664, bishopj@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: April 12, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08199 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Deferred 

Application From CHHD–C Developmental 

Biology. 

Date: April 29, 2022. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6710B Rockledge Drive, Room 2131B, 

Bethesda, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Jolanta Maria Topczewska, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, National Institutes 

Health, 6710B Rockledge Drive, Rm. 2131B, 

Bethesda, MD 20892, (301) 451–0000, 

jolanta.topczewska@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research, National Institutes of Health, HHS) 

Dated: April 12, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08205 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of federally 

funded research and development. 

Foreign patent applications are filed on 

selected inventions to extend market 

coverage for companies and may also be 

available for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Yogikala Prabhu, Ph.D., 301–761–7789; 

prabhuyo@niaid.nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases (NIAID), 5601 

Fishers Lane, Rockville, MD 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished 

information related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Novel Methods of MHC–I—LILRB 

Checkpoint Inhibition 

Description of Technology: The 

technology encompasses antibodies and 

methods that may overcome the 

shortcomings of commercial checkpoint 

inhibitors (CPIs). Scientists at NIAID 

have identified MHC–I specific 

antibodies that selectively inhibit 

interactions with inhibitory leukocyte 

immunoglobin-like receptors (LILRs) 

but not T-cell receptors. Administration 

of the antibodies increased proliferation 

and activation of both innate and 

adaptive immune system cells, and lead 

to anti-tumor and anti-viral activity in 

an array of relevant mouse models of 

disease. 

Immune CPIs that target PD–1/PD–L1, 

CTLA–4 and other well-known 

molecules can provide significant 

clinical benefit as part of a mono or 

combination immunotherapy regimen. 

However, many patients do not respond 

to treatment, leading to an ongoing 

search for novel checkpoint targets. One 

attractive family of targets are the 

inhibitory Leukocyte Immunoglobinlike receptors (LILRB1–5). LILRB1, 

LILRB2, and LILRB5 can inhibit 

immune cell function by binding to 

many MHC–I subtypes. However, 

LILRB1/2/5 expression is variable and 

the three members cannot be targeted by 

any single blocking anti-LILB antibody, 

possibly limiting the efficacy of 

targeting LILRBs. NIAID scientists have 

circumvented these issues by 

identifying antibodies that can inhibit 

LILRB function by binding to MHC–I 

without interfering with T-cell receptor 

engagement. 

To date, the MHC–I specific 

antibodies have been shown to induce 

activation and proliferation of human T 

cells and NK cells in xenogeneic models 

using NSG mice. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 


khammond on DSKJM1Z7X2PROD with NOTICES
22934 Federal Register / Vol. 87, No. 74 / Monday, April 18, 2022 / Notices 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Anti-tumor checkpoint inhibitor 

• Anti-viral checkpoint inhibitor 

Competitive Advantages: 

• Activation of innate (NK) and 

adaptive (CD8+ and CD4+) immune 

cell types 

• Causes proliferation and activation of 

immune effector cells regardless of 

target expression in tumors 

Development Stage: 

• Pre-clinical 

Inventors: Ethan M. Shevach, M.D. 

(NIAID), Abir Panda, Ph.D. (NIAID), 

David H. Margulies, M.D., Ph.D. 

(NIAID), and Kannan Natarajan, Ph.D. 

(NIAID). 

Publications: Panda, Abir, et al. 

‘‘Cutting Edge: Inhibition of the 

interaction of NK inhibitory receptors 

with MHC class I augments anti-viral 

and anti-tumor immunity.’’ J Immunol. 

2020.04.01.437942 

Intellectual Property: HHS Reference 

No. E–160–2021–0; US provisional 

application No. 63/262,120 filed on 

October 5, 2021. 

Licensing Contact: To license this 

technology, please contact Yogikala 

Prabhu, Ph.D., 301–761–7789; 

prabhuyo@niaid.nih.gov, and reference 

E–160–2021–0. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Yogikala Prabhu, Ph.D., 301– 

761–7789; prabhuyo@niaid.nih.gov. 

Dated: April 12, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–08150 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Minority Health 

and Health Disparities; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council on Minority Health and Health 

Disparities. 

The meeting will be held as a virtual 

meeting and is open to the public as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations to view the meeting, 

should notify the Contact Person listed 

below in advance of the meeting. The 

open session will be videocast and can 

be accessed from the NIH Videocasting 

and Podcasting website (https://

videocast.nih.gov/). 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National 

Advisory Council on Minority Health 

and Health Disparities. 

Date: May 23, 2022. 

Closed: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Name of Committee: National 

Advisory Council on Minority Health 

and Health Disparities. 

Date: May 24, 2022. 

Open: 11:00 a.m. to 4:00 p.m. 

Agenda: Opening Remarks, 

Administrative Matters, Director’s 

Report, Presentations, and Other 

Business of the Council. 

Place: National Institutes of Health, 

6707 Democracy Boulevard, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Monica Webb 

Hooper, Ph.D., Deputy Director, 

National Institute on Minority Health 

and Health Disparities, National 

Institutes of Health, 6707 Democracy 

Boulevard, Suite 800, Bethesda, 

Maryland 20892–5465, 301–402–1366, 

monica.hooper@nih.gov. 

Any interested person may file 

written comments with the committee 

by forwarding the statement to the 

Contact Person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: NIMHD: 

https://www.nimhd.nih.gov/about/ 

advisory-council/, where an agenda and 

any additional information for the 

meeting will be posted when available. 

Dated: April 12, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08201 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; R25 Application 

Review. 

Date: April 27, 2022. 

Time: 10:00 a.m. to 11:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6707 

Democracy Blvd., Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: John F. Connaughton, 

Ph.D., Chief, Scientific Review Branch, 

Review Branch, DEA, NIDDK, National 

Institutes of Health, Room 7007, 6707 

Democracy Boulevard, Bethesda, MD 20892– 

5452, (301) 594–7797, connaughtonj@

extra.niddk.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 12, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08196 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES